Industry Relations Council
AANN Industry Relations Council (IRC) membership is available to organizations that support the goals and mission of AANN.
The goal of the IRC is to provide a platform to form meaninful relationships and foster dialogue among industry representatives, to gain a greater understanding of mutual areas of interest, and to further programs that benefit patients and their families, neuroscience nurses, and other allied healthcare professionals.
Partnership agreements are renewed anually. The IRC program features tiered participation levels to allow companies of all sizes to enhance their engagement with AANN.
Benefits of IRC participation include
- Annual meeting between company representatives and a select group of AANN Board members and staff to discuss topics of mutual interest
- The ability to survey the AANN Membership
- Opportunity to send a dedicated e-blast to AANN members (sent by AANN on your behalf)
- Registration for the AANN Annual Conference
- Invitation to the President's Reception with AANN Board members
- Year-round recognition on the AANN website, on signage at the Annual Conference, and on the conference website.
To learn more about partnering with AANN, please contact Olivia Diehl at odiehl@aann.org.
Download the IRC Benefits and Application
Industry Relations Council Members
AANN proudly recognizes the following IRC corporate partners and thanks to them for their support. Please note, AANN does not endorse any company or product.
Executive Level
Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Our hhc mission is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.
To learn more about Eisai Inc., please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better."
More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live.
The Stellina™ Study
The Stellina Study is a Phase 1b/2a clinical study evaluating a single dose of diazepam intranasal spray (VALTOCO®) as a rescue medication in children aged 2-5 who have been diagnosed with epilepsy. The objectives of the study are to assess the pharmacokinetics (PK) of diazepam after one intranasal dose of VALTOCO as well as assessing the long-term safety and tolerability in the six-month open-label extension.
Click here for more information and to enroll.
January 2020 Update:
Neurelis announces the FDA approval of VALTOCO, the first nasal seizure rescue medication for ages 6 and above – read the Press Release for details.
Patient service program, myNEURELIS™ (1-866-696-3873). For more information on VALTOCO, please visit www.valtoco.com
- MIND-TD questionnaire
- How to do an AIMS exam
AIMS scorecard (pg. 15) - Neurocrine Biosciences CPL Team 2023
Servier is a commercial stage, privately held pharmaceutical company. Launched by Servier Group, an organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of biotech.
View clinical trial information
Servier has approved products in glioma, cholangiocarcinoma, myelodysplastic syndrome, acute myeloid leukemia, and acute lymphoblastic leukemia and is a leader in oncology driving the science behind target mutant isocitrate dehydrogenase inhibition. To learn more, visit www.servier.us and follow us on LinkedIn.
The ServierONE patient services program is an all-in-one resource for help with the cost of treatment, determining insurance coverage, one-on-one support, and access to additional resources and educational tools. Visit the ServierONE website to learn more.
At UCB, patients are at the heart of everything we do, inspiring us and driving our scientific discovery. By fulfilling this commitment, more impactful medicines are on the horizon. With a team of approximately 8,300 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing in cutting-edge scientific research.